CIK 0001840233 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Xilio Therapeutics, Inc.
Sign in to watch- Ticker
- XLO
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 851623397
- Phone
- 617-833-1027
- Business address
- 828 WINTER STREET, WALTHAM, MA, 02451
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 8 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-06-14 | Curran Daniel J. Director | Grant or award · Stock Option (right to buy) | +25,000 | 25,000 | ||
| 2024-06-13 | Shannon James Samuel Director | Grant or award · Stock Option (right to buy) | +50,000 | 50,000 | ||
| 2024-06-13 | Brennan Aoife Director | Grant or award · Stock Option (right to buy) | +50,000 | 50,000 | ||
| 2024-05-01 | Brennan Kevin M. SVP, FINANCE AND ACCOUNTING | Grant or award · Stock Option (right to buy) | +20,000 | 20,000 | ||
| 2024-05-01 | Luptakova Katarina CHIEF MEDICAL OFFICER | Grant or award · Stock Option (right to buy) | +59,333 | 59,333 | ||
| 2024-05-01 | Frankenfield Christopher James CHIEF OPERATING OFFICER | Grant or award · Stock Option (right to buy) | +208,000 | 208,000 | ||
| 2024-05-01 | Russo Rene PRESIDENT AND CEO | Grant or award · Stock Option (right to buy) | +474,000 | 474,000 | ||
| 2024-04-02 | GILEAD SCIENCES, INC. 10% owner | Purchase | +485,250 | $0.76 | $369K | 7,345,473 |
| 2024-04-02 | GILEAD SCIENCES, INC. 10% owner | Purchase · Prefunded Warrants (right to buy) | +3,882,450 | $0.76 | $3.0M | 3,882,450 |
| 2024-02-08 | Atlas Venture Fund XI, L.P. 10% owner | Sale | −733 | $0.64 | $469 | 2,019,563 |
| 2024-02-08 | Atlas Venture Fund XI, L.P. 10% owner | Sale | −267 | $0.64 | $171 | 734,546 |
| 2024-01-12 | Atlas Venture Fund XI, L.P. 10% owner | Sale | −1,540 | $0.83 | $1K | 2,020,296 |
| 2024-01-12 | Atlas Venture Fund XI, L.P. 10% owner | Sale | −560 | $0.83 | $465 | 734,813 |
| 2024-01-11 | Atlas Venture Fund XI, L.P. 10% owner | Sale | −1,566 | $0.87 | $1K | 2,021,836 |
| 2024-01-11 | Atlas Venture Fund XI, L.P. 10% owner | Sale | −569 | $0.87 | $495 | 735,373 |
| 2024-01-01 | Frankenfield Christopher James CHIEF OPERATING OFFICER | Grant or award · Restricted Stock Units | +77,500 | 77,500 | ||
| 2024-01-01 | Luptakova Katarina CHIEF MEDICAL OFFICER | Grant or award · Restricted Stock Units | +66,500 | 66,500 | ||
| 2024-01-01 | Brennan Kevin M. SVP, FINANCE AND ACCOUNTING | Grant or award · Restricted Stock Units | +20,000 | 20,000 | ||
| 2024-01-01 | Russo Rene PRESIDENT AND CEO | Grant or award · Restricted Stock Units | +177,000 | 177,000 | ||
| 2023-09-05 | Luptakova Katarina Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +106,000 | 106,000 |
Page 7 of 12 · 224 trades